Barclays
RCUS icon

Barclays’s Arcus Biosciences RCUS Stock Holding History

Barclays’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,265,900
Closed -$17.2M – 5595
2025
Q3 		$17.2M Hold
1,265,900
– – ﹤0.01% 1310
2025
Q2 		$10.3M Buy
+1,265,900
New +$10.8M ﹤0.01% 1564
2024
Q2 		– Sell
-27,000
Closed -$510K – 5223
2024
Q1 		$510K Buy
+27,000
New +$467K ﹤0.01% 3579

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Barclays's RCUS Position: Q1 2026 in Review

Barclays reduced its Arcus Biosciences (RCUS) stake by 93% in Q1 2026, selling an estimated $22.4M and leaving 74,977 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

Barclays first reported a position in RCUS in Q2 2018 and has held it in 32 quarters since. The position peaked at $26.5M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Barclays held 74,977 shares of Arcus Biosciences worth $1.62M as of Q1 2026.
  • Barclays sold 1,037,281 Arcus Biosciences shares in Q1 2026, an estimated $22.4M.
  • Arcus Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2489 holding.
  • Barclays first reported a position in Arcus Biosciences in Q2 2018 and has held it in 32 quarters since.
  • Barclays's Arcus Biosciences position peaked at $26.5M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.